Overview Dividends

(INSP) Inspire Medical Systems - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4577301090

Neurostimulation, System, Sensor, Stimulator, Therapy

INSP EPS (Earnings per Share)

EPS Growth (3Y CAGR): -5.73%
EPS Trend (3Y Correlation): 50.6%

INSP Revenue

Revenue Growth (3Y CAGR): 28.39%
Revenue Trend (3Y Correlation): 92.5%

Description: INSP Inspire Medical Systems November 08, 2025

Inspire Medical Systems, Inc. (NYSE: INSP) develops and markets the Inspire™ system-a minimally invasive, neurostimulation device that delivers closed-loop hypoglossal nerve stimulation to keep the airway open for patients with moderate to severe obstructive sleep apnea (OSA) in the U.S. and abroad. The company, founded in 2007 and based in Golden Valley, Minnesota, positions the technology as an alternative to continuous positive airway pressure (CPAP) therapy.

Key industry and company metrics that shape its outlook include: (1) the U.S. OSA treatment market, estimated at roughly $5 billion in 2023 and growing at ~6 % CAGR, driven by rising obesity rates and greater diagnostic awareness; (2) Inspire’s FY2023 revenue of $84 million, reflecting a 42 % year-over-year increase after the 2022 FDA approval of its next-generation device; and (3) reimbursement dynamics, where Medicare’s coverage of hypoglossal nerve stimulation has expanded to include certain Medicare Advantage plans, improving payer acceptance but still leaving a gap in private-insurer coverage that could affect adoption rates.

For a deeper quantitative assessment of INSP’s valuation and risk profile, you may find ValueRay’s analyst toolkit useful.

INSP Stock Overview

Market Cap in USD	2,132m
Sub-Industry	Health Care Technology
IPO / Inception	2018-05-03

INSP Stock Ratings

Growth Rating	-81.8%
Fundamental	80.8%
Dividend Rating	-
Return 12m vs S&P 500	-64.2%
Analyst Rating	4.17 of 5

INSP Dividends

Currently no dividends paid

INSP Growth Ratios

Growth Correlation 3m	-63.8%
Growth Correlation 12m	-96%
Growth Correlation 5y	-48.5%
CAGR 5y	-27.80%
CAGR/Max DD 3y (Calmar Ratio)	-0.36
CAGR/Mean DD 3y (Pain Ratio)	-0.73
Sharpe Ratio 12m	-0.86
Alpha	-78.82
Beta	1.159
Volatility	51.56%
Current Volume	762.3k
Average Volume 20d	993.5k
Stop Loss	77.3 (-5.5%)
Signal	1.80

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (53.1m TTM) > 0 and > 6% of Revenue (6% = 51.7m TTM)

FCFTA 0.11 (>2.0%) and ΔFCFTA 11.89pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 55.71% (prev 76.73%; Δ -21.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 117.4m > Net Income 53.1m (YES >=105%, WARN >=100%)

Net Debt (-73.9m) to EBITDA (81.2m) ratio: -0.91 <= 3.0 (WARN <= 3.5)

Current Ratio 6.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (29.5m) change vs 12m ago -2.96% (target <= -2.0% for YES)

Gross Margin 84.47% (prev 84.83%; Δ -0.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 112.5% (prev 96.89%; Δ 15.66pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 2709 (EBITDA TTM 81.2m / Interest Expense TTM 26.0k) >= 6 (WARN >= 3)

Altman Z'' 0.89

(A) 0.60 = (Total Current Assets 573.2m - Total Current Liabilities 93.4m) / Total Assets 802.2m

(B) -0.36 = Retained Earnings (Balance) -292.5m / Total Assets 802.2m

(D) -2.35 = Book Value of Equity -292.1m / Total Liabilities 124.4m

Total Rating: 0.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 80.78

1. Piotroski 7.0pt = 2.0

2. FCF Yield 4.56% = 2.28

3. FCF Margin 9.87% = 2.47

4. Debt/Equity 0.05 = 2.50

5. Debt/Ebitda -0.91 = 2.50

6. ROIC - WACC (= 7.13)% = 8.91

7. RoE 7.87% = 0.66

8. Rev. Trend 92.46% = 6.93

9. EPS Trend 50.57% = 2.53

What is the price of INSP shares?

As of November 08, 2025, the stock is trading at USD 81.79 with a total of 762,256 shares traded.
Over the past week, the price has changed by +13.47%, over one month by +6.47%, over three months by +6.15% and over the past year by -59.20%.

Is Inspire Medical Systems a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Inspire Medical Systems (NYSE:INSP) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 80.78 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INSP is around 56.31 USD . This means that INSP is currently overvalued and has a potential downside of -31.15%.

Is INSP a buy, sell or hold?

Inspire Medical Systems has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy INSP.

Strong Buy: 8
Buy: 5
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the INSP price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	117.4	43.5%
Analysts Target Price	117.4	43.5%
ValueRay Target Price	63.7	-22.1%

INSP Fundamental Data Overview November 04, 2025

Market Cap USD = 2.13b (2.13b USD * 1.0 USD.USD)
P/E Trailing = 41.4253
P/E Forward = 49.7512
P/S = 2.475
P/B = 3.2327
Beta = 1.159
Revenue TTM = 861.3m USD
EBIT TTM = 70.4m USD
EBITDA TTM = 81.2m USD
Long Term Debt = 33.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.15m USD (from shortTermDebt, last quarter)
Debt = 33.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -73.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.86b USD (2.13b + Debt 33.1m - CCE 300.9m)
Interest Coverage Ratio = 2709 (Ebit TTM 70.4m / Interest Expense TTM 26.0k)
FCF Yield = 4.56% (FCF TTM 85.0m / Enterprise Value 1.86b)
FCF Margin = 9.87% (FCF TTM 85.0m / Revenue TTM 861.3m)
Net Margin = 6.17% (Net Income TTM 53.1m / Revenue TTM 861.3m)
Gross Margin = 84.47% ((Revenue TTM 861.3m - Cost of Revenue TTM 133.8m) / Revenue TTM)
Gross Margin QoQ = 84.03% (prev 84.75%)
Tobins Q-Ratio = 2.32 (Enterprise Value 1.86b / Total Assets 802.2m)
Interest Expense / Debt = 0.01% (Interest Expense 4000 / Debt 33.1m)
Taxrate = -54.03% (out of range, set to none) (1.26m / -2.33m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 6.14 (Total Current Assets 573.2m / Total Current Liabilities 93.4m)
Debt / Equity = 0.05 (Debt 33.1m / totalStockholderEquity, last quarter 677.8m)
Debt / EBITDA = -0.91 (Net Debt -73.9m / EBITDA 81.2m)
Debt / FCF = -0.87 (Net Debt -73.9m / FCF TTM 85.0m)
Total Stockholder Equity = 675.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.62% (Net Income 53.1m / Total Assets 802.2m)
RoE = 7.87% (Net Income TTM 53.1m / Total Stockholder Equity 675.0m)
RoCE = 9.95% (EBIT 70.4m / Capital Employed (Equity 675.0m + L.T.Debt 33.1m))
RoIC = 17.26% (EBIT 70.4m / (Assets 802.2m - Curr.Liab 93.4m - Cash 300.9m))
WACC = 10.13% (E(2.13b)/V(2.16b) * Re(10.29%) + (debt cost/tax rate unavailable))
Discount Rate = 10.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.21%
[DCF Debug] Terminal Value 61.04% ; FCFE base≈85.0m ; Y1≈55.8m ; Y5≈25.5m
Fair Price DCF = 12.24 (DCF Value 362.0m / Shares Outstanding 29.6m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 50.57 | EPS CAGR: -5.73% | SUE: 1.56 | # QB: 10
Revenue Correlation: 92.46 | Revenue CAGR: 28.39% | SUE: 0.58 | # QB: 0

Additional Sources for INSP Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle